Novo Nordisk’s 20% Rally Masks a Fundamental Gap and an FDA Clock That Hasn’t Run Out

Novo Nordisk rebounds 19.5% but remains 28.9% below its all-time high. Fair value estimate at $97, RSI signals overbought. Pipeline drug CagriSema awaits FDA decision, while market share slips to 40%.

Novo Nordisk has clawed back nearly a fifth of its value in the past month, closing Friday at €43.50 after a 19.52% advance. Yet the stock remains 28.92% below last July’s all-time high of $61.20, and the Relative Strength Index stands at 71.2 – territory that normally signals a pause is overdue. The rally has been fuelled by a €15 billion share buyback programme and growing enthusiasm for the oral version of Wegovy, but the biggest catalyst investors are betting on has not even been decided.

The Fair-Value Case That Won’t Go Away

While the technical picture looks stretched, the fundamental argument for owning Novo Nordisk has rarely been louder. A valuation model by Simply Wall St puts the stock’s fair value at roughly $97 – a level that implies the current share price leaves a massive discount on the table. The calculation is anchored on free cash flow of around 48 billion Danish kroner. Even on standard earnings multiples the paper appears cheap: Novo Nordisk trades at a price-to-earnings ratio of 12.1, compared with a sector average of 15.4 and peers that sometimes command multiples above 25.

The board is backing that assessment with cash. A buyback programme of up to 15 billion kroner is under way, and the company had repurchased nearly 6 billion kroner worth of its own shares by the end of June. That steady demand has helped put a floor under the stock during a period when broader sentiment toward the GLP-1 sector has been mixed.

CagriSema: The Missing Piece of the Puzzle

The rally’s true driver, however, is not buybacks but a pipeline bet that remains unresolved. Novo Nordisk submitted its amylin-GLP-1 combination CagriSema to the US Food and Drug Administration in December 2025, with a decision expected in the fourth quarter of 2026. In the REDEFINE 4 phase III trial, CagriSema achieved a 23% weight loss but failed to meet the primary endpoint against Eli Lilly’s Zepbound (15 mg) over 84 weeks – it was statistically non-inferior but not superior.

That mixed result is the central tension. Supporters point to new diabetes data presented at the American Diabetes Association 2026 meeting, where CagriSema showed better glycaemic control and weight reduction than any monotherapy in the REIMAGINE programme. They also highlight the commercial success of oral Wegovy: more than one million Americans started taking it within four months of launch, and an international rollout is planned for the second half of 2026. If the FDA grants a favourable label for obesity, the argument goes, the current technical strength could be justified by fundamentals later this year.

The Bear Case: Market Share Fading and Generics Biting

Sceptics counter that Novo Nordisk is losing ground in a market it once dominated. Most estimates now give the Danish group only about 40% of the GLP-1 market, while Eli Lilly has captured roughly 60%. Morgan Stanley analyst Thibault Boutherin continues to favour Lilly over Novo Nordisk, citing superior efficacy data and rising generic pressure on the Danish company’s legacy products.

Deutsche Bank analysts have also flagged headwinds. Patent expirations are starting to bite, and an increasing number of competitors are entering the obesity and diabetes therapy space. That combination – falling market share, looming generics and the statistical disappointment of CagriSema’s head-to-head with Zepbound – explains why investors have been reluctant to award the stock a higher valuation.

Technical Levels and the Next Catalyst

With the RSI in overbought territory and the FDA decision still several months away, the near-term path looks set for consolidation. The stock closed Friday above its 200-day moving average of €40.80, which has acted as a key support level during the rally. A break below that could pressure the 50-day moving average at €38.72, a level the primary article’s model indicated as a potential test zone near €40.

The next concrete catalyst is the FDA verdict on CagriSema, expected in Q4 2026. Until then, the stock is likely to oscillate between pipeline optimism and the harsher reality of market share erosion. For longs, the gap between a fair value of $97 and today’s price offers a compelling entry – but only if the regulatory clock ticks in Novo Nordisk’s favour.